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ABSTRACT
DNA methylation is a vital epigenetic process that acts as a major control mechanism for
gene expression. In addition to its essential role in many normal cellular processes, it is also
implicated in a wide variety of disease states and processes including cancer. Along with genetic
mutations, aberrant DNA methylation patterns, specifically the inappropriate DNA methylation or
demethylation of CpG residues, may activate oncogenes or suppress tumor suppressor genes,
respectively. These changes can generate or facilitate the progression of tumorigenesis and tend to
accumulate throughout the development of cancer. Although they play such a major role in cancer
and in other diseases, it remains unclear what causes these epigenetic revisions to occur. This
dissertation will focus on uncovering mechanisms that are sources of epigenetic revision, specifically
as they relate to cancer.
Due to rapid cell division and increased DNA damage, cells are increasingly dependent on
DNA repair as they continue on a path of tumorigenic progression. We hypothesize that DNA
repair, specifically the repair of DNA double strand breaks (DSB) by Non-Homologous End Joining
(NHEJ) may play a role in inappropriate epigenetic revision. Using a GFP reporter system inserted
into the genome of HeLa cells, we are able to induce targeted DNA damage that enables the cells,
after successfully undergoing NHEJ repair, to express WT GFP. These GFP+ cells were segrega ted
into two expression classes, one with robust expression (Bright) and the other with reduced
expression (Dim). Using a DNA hypomethylating drug (AzadC) we were able to demonstrate that
the different GFP expression levels was due to differential methylation statuses of CpGs in regions
on either side of the break site. Deep sequencing analysis of this area in sorted Bright and Dim
populations revealed a collection of different epi-alleles that display patterns of DNA methylation
iii

following repair by NHEJ. These patterns differ between Bright and Dim cells which are hypo- and
hypermethylated, respectively, and between the post-repair populations and the original, uncut cells.
These data suggest that NHEJ repair facilitates a rewrite of the methylation landsca pe in repaired
genes, elucidating one potential source for the altered methylation patterns seen in cancer cells.
The Dim cells generated during this study are known to have a hypermethylated GFP gene
that is correlated with reduced expression, allowing it to be used as a screening tool for
hypomethylating agents. We used this tool to screen the blood serum of patients with head and neck
squamous cell carcinoma (HNSCC). We found that the serum from HNSCC patients, but not from
healthy individuals, contains some factor that causes hypomethylation in exposed cells. Further, we
were able to identify this factor as a protein capable of effecting changes in DNA methylation, gene
expression, and miRNA levels in the treated Dim cells. The novel concept presented in this study
has immense implications on the study of cancer progression as it evidences circulating proteins,
presumably released by cancer cells, which are able to effect gene expression in cells that are distal to
the location of the cancer. Further, the fact that these proteins are in circulation makes them a
potential target for use in diagnostics.
Changes in DNA methylation play a major role in the development of cancer and
understanding the mechanisms by which this occurs could provide new therapeutic targets for
preventing this process from contributing to tumorigenesis. This dissertation presents potential
sources of epigenetic revision in cancer and thus provides answers to a major question that has yet
to be answered in the area of cancer research.
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CHAPTER ONE: INTRODUCTION

Epigenetics
An organism’s characteristics are a result of two layers of information; the first is the
message that is contained in their genetic code and the second is how that code is read and
implemented. The study of the information contained in the genetic code is termed genetics, while the
study of how the genetic information is expressed is termed epigenetics. Since all of an organism’s cells
contain the same genetic code (barring stochastic DNA mutations), it is epigenetics which ultimately
shape the specific characteristics of a cell as they change and control gene expression levels.
This is accomplished by mechanisms that physically alter chromatic configuration to
manage what genes are accessible to transcription machinery, including DNA methylation, histone
modifications, or RNA-associated silencing. Genes that are available to transcription machinery are
transcribed while those that are hidden are repressed, allowing cells with the same genetic makeup to
have vastly different characteristics. Although epigenetic information is alterable, it is also heritable
so that cells are able to produce daughter cells with the same gene expression profile. This process
is essential for generating the different cell types with different functions that make up an organism.

DNA methylation
The first level of epigenetic regulation occurs by marking specific locations of the DNA
strand itself using DNA methylation. DNA may be methylated on cytosine residues of CpG islands
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by the catalytic activity of DNA methyltransferases (DNMTs). DNMTs catalyze the addition of a
methyl group, which is donated by the cofactor S-adenosylmethionine (SAM), to the carbon at
position 5 of the pyrimidine ring of cytosine residues to generate 5-methylcytosine (1). Methylation
profiles are passed from parent to daughter cells by DNMT 1, a maintenance DNMT that copies
methylation patterns of hemimethylated DNA from the template strand to the newly synthesized
strand during DNA replication. DNMT3a and 3b act as de novo methyltransferases, adding methyl
groups to previously unmethylated CpG residues. DNMT1 has also been shown to have some de
novo methyltransferase activity under certain conditions (1,2).
DNA methylation may be classified as either invariant and stable (sex-specific imprinting) or
metastable. In somatic cells, DNA methylation is metastable and changes with age (3), diet (4,5),
environment (6), disease (7-10), or other external or intrinsic events (11). In these studies, we are
examining somatic, metastable DNA methylation. This epigenetic modification is usually associated
with gene silencing (12,13) as it interferes with transcription machinery and is recognized by proteins
that recruit histone modifiers to condense chromatin, an action which blocks the accessibility of
transcription machinery to the affected genes (14-16).

DNA methylation in cancer
Under normal conditions, epigenetic modifications serve to modulate gene expression
during embryonic development (17) and genomic imprinting (18), differentiation (19), or in response
to stimuli (20); however unscheduled changes in epigenetic modifications have been linked to
numerous health conditions including neurodegenerative (9), cardiovascular (21), imprinting-related
(22), and metabolic diseases (23) and are known to play a prominent role in the development of
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cancer. Incorrect revision of the normal epigenetic landscape can cause inappropriate gene silencing
of tumor suppressor genes or activation of oncogenes, a phenomenon that is seen in various types
of cancer cells (8,12,24,25).
Cancerous cells arise in a multi-step process as a result of an upset in the balance of
oncogenes and tumor suppressor genes that causes deregulation of normal epistasis. This imbalance
may derive from genetic mutations that affect this balance; however, changes in expression levels
can also be caused by inappropriate DNA methylation marks. Moreover, the addition or removal of
post-translational modifications to histones can affect the access of transcriptional machinery to
particular genes by opening or closing the chromatin, causing gene activation or repression,
respectively (13,24,26,27). Acetylation of histones, catalyzed by histone acetyltransferases (HATs)
causes activation of genes by reducing the affinity of histones for DNA and by acting as a docking
surface for other histone remodeling proteins (28). Histone deacetylases (HDACs), including
Sirtuins, work in reverse to repress transcription along with histone methyltransferases (29).
Both hypermethylation and hypomethylation can contribute to tumorigenesis when they
occur at inappropriate positions in the genome. DNA hypermethylation is generally associated with
gene silencing while hypomethylated is associated with gene activation (8,24). Changes in the
cellular DNA methylome resulting in hypermethylation of tumor suppressor genes including APC,
BRCA1, E-cadherins, DAPK1, hMLH1, p15, Rb, MGMT, and p16INK4a have been documented
in tumors from a variety of cancers including breast, colon, gastric, ovarian, lung, brain, ovarian,
renal, kidney, prostate, thyroid, lymphoma, and leukemia (8,13,24). Hypomethylation has also been
shown to contribute to tumorigenesis by over-activating oncogenes and contributing to genetic
instability and structural changes by promoting an open chromatin state (8,30)
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Coordination of genetic and epigenetic processes
Cancer cells coordinate genetic mutations and epigenetic revision in order to promote
carcinogenesis. According to the two-hit hypothesis, a tumor suppressor gene must be deactivated in
both alleles in order to cause cancer. HCT116 colon cancer cells were found to have genetic
mutations in one allele of both CDKN2a and MLH1 and epigenetic silencing of the second allele,
demonstrating the collaboration of genetic mutation and hypermethylation in achieving the second
‘hit’ to cause loss of heterozygosity and inactivation a tumor suppressor gene (8). Both
hypermethylation and hypomethylation can also contribute to cancer progression by promoting
mutagenic processes. This is observed in the silencing of genes involved in DNA repair via
hypermethylation, which results in defective repair pathways and increased DNA mutagenesis
(26,31). In addition, hypomethylation can cause over expression of an oncogene due to the loss of
genomic imprinting that results in the expression of both alleles instead of only one allele (32,33),
and hypomethylation of LINE retrotransposons facilitates insertion mutagenesis (34,35). Further,
mutations or dysregulation of epigenetic regulation proteins can propagate DNA methylation
changes in other areas of the genome.
Although DNA methylation changes are known to play a major role in the development and
progression of cancer, the mechanism(s) involved in effecting these changes remain unresolved. It is
the goal of this dissertation to investigate and identify sources that may generate and propagate
epigenetic revision during the process of carcinogenesis.
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CHAPTER TWO:

Introduction
DNA damage and repair
In order to pass the G2 checkpoint and enter mitosis, cells must repair any DNA damages
that have occurred. Double stranded breaks in DNA (DSBs), in which breaks occur in both strands
of the DNA double helix in close proximity to one another, are the most dangerous damage for a
cell (36,37). These breaks can be caused by both exogenous and endogenous sources including
reactive oxygen species, ionizing radiation (38), replication fork collapse (36,39), or the faulty action
of nuclear enzymes such as topoisomerase II (40,41).
Regardless of origin, DSBs are fatal to the cell if not repaired. When faced with such a
damage, the cell must repair the damage in order to survive or continue dividing (36). Double strand
breaks are repaired by one of two pathways in Eukaryotic cells (42). During S and G2 phases of the
cell cycle, when DNA has been replicated and exists in pairs of sister chromatids, the cell is able to
fix the breaks with the high fidelity process of Homology Dependent Repair (HDR) (43,44). This
process involves resection of one strand of a broken end to produce a single stranded overhang that
can invade the helix of the sister chromatid. Polymerase then uses the sister chromatid to fill in
sequence on the broken ends and the strands are resolved to separate, complete sister chromatids
(40,45).
During the rest of the cell cycle, or in non-dividing cells, no identical sequence template is
available to allow HDR to proceed, so the cell turns to the faster but more error prone process of
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Non-Homologous End Joining (NHEJ) (46,47). This process proceeds through recognition and
binding of the broken ends by Ku 70-80 proteins and DNA-PKcs (48). Together, this complex has a
role similar to that of Proliferating Cell Nuclear Antigen (PCNA) during replication as it acts as a
docking platform for other proteins. During repair, these other proteins are nuclease, polymerase,
and ligase complexes needed to process the repair. The DNA-PKcs complex with Artemis has 3’
and 5’ endonuclease as well as 5’ exonuclease activity, allowing it to process a diverse array of
damaged DNA ends. Polymerases μ and λ are also able to interact with the complex, allowing
flexible and template-independent synthesis. The processing of DNA ends during NHEJ is not fully
understood and is not the same for each break; even identical breaks in the same location show
variation in end processing (48). Blunted DNA ends are subsequently ligated through the action of
XLF:XRCC4:DNA ligase IV complex. Although the immediate threat to the cell is averted by repair
of the DSB, repair by NHEJ often results in deletions or frame shifts in the repaired area as a result
of end processing. This process is a major source of DNA mutation in arrested cells (49). Despite its
limitations, the quick kinetics and ability to repair without a template make NHEJ the repair pathway
of choice in cells outside of S and G2 and in non-dividing cells. It is the predominant DSB repair
pathway in animal cells since it occurs throughout the cell cycle (46,47).

Methylation, repair, and HDR
Studies of HDR have determined that, following repair, some cells exhibit robust expression
of the repaired gene while others show low expression levels. It was determined that these
expression classes arise as a result of epigenetic reprogramming, more specifically, altered CpG
methylation at the repair site (50-52). In addition, specific DNA methyltransferases have been found
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to localize at DNA repair sites (50). During S phase, DNMT1 methylates hemimethylated DNA
during replication, copying the methylation profile of the parental DNA strand to the daughter
strand, a process which is also ongoing when DNA methylation is altered post-HDR (50,53). Thus,
DNA methylation exists in a triad of dynamic, interworking processes along with DNA replication
and HDR.
The mechanism for DNMT-mediated methylation at repair sites following NHEJ, which
occurs independently of DNA replication, is less well understood despite being a prominent DNA
repair pathway in animal cells. We address this topic in the current paper. Specifically, in this work,
we report the following observations. First, NHEJ repair pathway attended by DNA methylation
revision in somatic human cells. Second, specific methylation sites map on the repaired gene to sites
that are distinctly different from those seen in the HDR pathway (50). Third, we show that
epigenetic revisions driven by NHEJ are stably inherited. In this work, we used a neutral gene to
report alterations in DNA methylation to ensure that selective pressure post repair would not
influence our ability to track the NHEJ descendants. Collectively, the data supports the notion that
the prominent DNA repair pathway in animal cells is a source of genetic diversity but also a source
of epigenetic (or gene expression) change in cases where a wild type allele is recovered post -NHEJ.
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Materials and Methods
Cell culture
The stable HeLa cell line was cultured in RPMI medium with L-glutamine and supplemented
with 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were grown in at 37°C at 5%
CO .
2

Stable cell line
HeLa cells were transfected with a Tet-On inducible gene expression system (Clontech) and
set to target the I-Sce1 gene according to the Tet-On system manual. After generation of a stable
Tet-On cell line, the cells were transfected with the GFP reporter construct for NHEJ provided by
the Gorbunova lab (54). These cells were grown under selective pressure with Geneticin (G418) to
generate the stable iHN20.22 cell line containing the reporter construct and a tetracycline inducible
I-Sce1 gene.

Tet On promoter activation
IHN20.22 cells were treated with 1µg/mL doxycycline for varying durations to determine
the optimal induction time. It was determined that a 24-hour pulse of doxycycline was sufficient to
induce the NHEJ system, so this was used in future experiments.
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FACS analysis
IHN20.22 cells were trypsinized and centrifuged at 1000xg for 5 minutes and then and resuspended in PBS at a density of 10 cells/mL. Live cells were selected using a plot of SSC-A vs.
6

FSC-A, and GFP positive cells were identified using a plot of FSC-A vs FL1A-A. The FL1-A
histogram was then used to identify and gate the distinct populations of low and high expressing
cells.

Live-Cell Imaging
Cells were seeded at low density in glass bottom culture dishes (MatTek) induced with Dox
for 24 hours and then placed into an incubation chamber that is part of a Perkin Elmer UltraVIEW
VoX 3D Live Cell Imaging System attached to a Zeiss Axio Observer Z1 inverted fluorescence
microscope. Images were taken every 5 minutes for the next 48 hours and then ana lyzed using
Volocity Imaging and Analysis software (Perkin Elmer).

Drug treatments
IHN20.22 cells were plated at low confluence and induced with doxycycline for 24 hours.
After 24 hours, media was removed and replaced with fresh media and cells were given a daily dose
of 1µM 5-AzadC or 1% DMSO control for 48 hours (unless otherwise noted) and then were
harvested for FACS analysis.

9

Cell sorting
Dox induced IHN 20.22 cells were treated with dox for 24 hours and then grown under
normal culture conditions until the GFP expression levels stabilized. Cells were then harvested and
re-suspended in median containing RPMI, 1% penicillin-streptomycin, 20mM Hepes buffer, and 2%
FBS at a density of 3x10 cells/mL. Cells were run through FACSAria flow cytometer and sorted by
6

using the FSC-A and FITC-A plot to gate GFP positive cells and then using the histogram of FITCA to select ‘dim’ and ‘bright’ populations. Two sorted populations (Bright and Dim) were collected
in a tube containing media supplemented with 30% FBS and then transferred to culture dishes
containing culture medium (RPMI supplemented with 10% FBS and 1% Penicillin-streptomycin) at
37°C at 5% CO .
2

Bisulfite Converted DNA preparation
Genomic DNA was extracted from iHN20.22 cells (uncut) as well as the sorted bright and
dim populations using Wizard genomic DNA purification kit” (Promega). 100ng of extracted DNA
was used for bisulfite conversion using the Epijet Bisulfite Conversion Kit (Thermoscientific).
Regions on either side of the repair site in bisulfite converted DNA were amplified using Phusion U
Hot Start Polymerase (Thermoscientific) and 5 sets of primers (Table 2). The 5 PCR fragments of
each sample (uncut, sorted Dim, and sorted Bright) were purified using GENEjet PCR purification
kit (Thermoscientific).
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Bisulfite Sequencing
These samples were transferred to the core sequencing facility at Sanford Burnham at Lake
Nona, Orlando Florida. Illumina’s Truseq ChIP Library Preparation kit was used to prepare a total
of 15 libraries (5 fragments each for 3 samples: uncut, sorted Dim, and sorted Bright) from 10ng of
input DNA. Quality and quantity of the libraries were analyzed using an Agilent Bioanalyzer and
Kapa Biosystems qPCR. The Multiplexed libraries were pooled and subjected to Paired-end 2x250bp sequencing using one flow-cell of a Miseq sequencing instrument.

Methylation analysis
FastQ files were subjected to quality check using FASTQC software
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). Then, paired-end reads from the
sequencer platform were merged together using PEAR tool (55) with a minimum of 40 overlapping
residues as threshold (mean PHREAD score of at least 33) and merged FastQ files were converte d
in Fasta using Prinseq (56). To analyze the methylation status of each amplicon, we used
AMPLIMETHPROFILER (57) specifically designed for deep targeted bisulfite amplicon
sequencing of multiple genomic regions. This pipeline is freely available at
https://sourceforge.net/projects/amplimethprofiler and is organized as follows: first, it recognizes
corresponding target region discarding PCR artifacts and reads that do not match expected lengths;
then, reads are aligned to the corresponding bisulfite-converted reference using BLASTn (58). We
used very stringent parameters: fragment length threshold, 50%; threshold alignment primers, 80%;
bisulfite conversion efficiency, 99% and threshold alignment to reference, 50%. The pipeline output
format reports the methylation status for each CpG dinucleotide coded 0 as non-methylated, 1 as
11

methylated, and 2 if the methylation state cannot be assessed. We use this output to perform the
analysis. Quantitative methylation average for each site is represented by the ratio between the
number of non-converted bases at that site and the total number of mapped reads. The abundance
of each of the 2NCpG distinct epialleles (where NCpG stands for the number of CpG sites in the
analyzed region) was evaluated for each sample by counting the number of passing filter reads
containing that epiallele. Qualitative methylation analysis was performed using Qiime (59), which
includes: 1. a “summary”, the number of profiles present in each input sample; 2. a
“taxa_summary_plots” , the information on the distribution of methylation profile classes; 3. “alpha
diversity” , the five alpha diversity metrics for each sample: a. number of different methylation
profiles in the sample; b. shannon entropy; c. simpson index; d. Chao 1 index ; e. number of
singletons. Such metrics were computed through a rarefaction procedure to take into account biases
derived from variable sequencing depth and; 4. “beta Diversity”, the distance between samples in
terms of composition of their methylation profiles, measured by Bray–Curtis dissimilarity: 5. PCoA
Principal Coordinates analysis.

Results
A neutral reporter system for analysis of epigenetic revision during NHEJ.
In order to study the NHEJ repair pathway, we have generated a HeLa cell line containing a
GFP based reporter construct (54,60) (Figure 1). The construct contains a CMV driven GFP gene
that was interrupted by a rodent Pem1 intron. Within this intron, an adenoviral exon was added that
is flanked by two restriction sites for the megaendonuclease, I-Sce1. There are no I-Sce1 sites in the
12

human genome; Thus DSB are target to these twin sites. The presence of the viral exon disrupts the
gene, and as a consequence, the cells are GFP negative; however, when I-SceI is introduced to the
cells, the adenoviral exon is excised by two DSBs and repaired by NHEJ. Since removal of the exon
allows the construct to generate WT GFP after splicing, cells have effectively undergone NHEJ
repair and some sub-fraction of the cells will be GFP positive (since NHEJ is error prone, we
cannot score mutant alleles with this assay based on GFP expression). In addition, there is no
homologous DNA template for the repair event; therefore, this is a dedicated NHEJ repair process
and HDR cannot proceed under these conditions. To improve accuracy and penetrance of the
system, the gene for I-SceI gene has been placed in these HeLa cells under control of a Tet-On
promoter, thus, the system is doxycycline inducible.

A segregation of expression classes following repair by NHEJ.
The NHEJ reporter system was tested by adding Doxycycline (Dox) to the media of the
IHN20.22 HeLa cells. We note that other clones tested behaved similarly; however, some clones
displayed higher backgrounds, probably due to leaky I-Sce1 expression in the absence of Dox.
IHN20.22 was selected since this clone exhibited low levels of GFP positive cells in the absence of
Dox. I-Sce1 induction was quite robust in IHN20.22 cells and within a few hours after Dox
addition, Western blots showed the presence of prominent amounts of I-Sce1 protein (data not
shown). At 24 hours post-Dox, GFP expressing cells could readily be seen by live imaging or
fluorescent microscopy. GFP levels could also be measured using flow cytometry (Figure 2). The
percentage of GFP positive cells steadily increases over time with continuous exposure to
Doxycycline, while in negative controls (no Dox) the percentage of GFP positive cells stays well
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under 1% which we attribute to leakiness of the Tet-On promoter, as noted. After a 24-hour pulse
with Dox, the percentage increases and then peaks at about 5-7% after four days (Figure 3). The
emergence of GFP positive cells can be observed via live imaging during the 72 hours following
induction with Doxycycline (Figure 4) as a GFP negative cell (circle, top image) undergoes NHEJ
repair and begins to express WT GFP as time progresses to the second image. Since the post -repair
cell now contains a WT GFP gene, division produces two GFP positive daughter cells in the last
image. By limiting the expression of I-Sce1 to 24 hours, the pulse-chase experimental schematic
allows for focused investigation of the processes that occur following a DSB without the added
variables of continuous DSB induction and continuous Dox treatment. Note that the scatter plots in
Figure 3 appear to contain dual populations of GFP positive cells (dashed rings). The two
populations, which appear to differ in total GFP expression levels were more clearly observable a fter
Dox induction with I-Sce1; however, in the negative controls, this heterogeneity was observed. This
was examined in more detail in order to understand the underlying basis for this observation.

GFP Expression is heterogeneous in repaired cell populations following NHEJ.
The histogram of GFP positive cells reveals the emergence of two expression classes with
differing GFP intensities. One class expresses GFP robustly while the other maintains lower
expression levels. We refer to these populations as Bright and Dim, respectively (Figure 5). To
determine if the differing expression classes may be a result of DNA methylation, we tested whether
the expression classes were altered by the DNA hypomethylating drug, 5’-Aza-2’-Deoxycytidine
(AzadC). This drug acts by inducing a stable, covalent complex between the methyl's and DNA
(50,61-63). The result is hypomethylation of the genome due to the sequestering of DNMTs that are
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covalently bound to DNA. This prevents further methyltransferase action and effectively inhibits
the overall DNA methylation of the cell. Based on this known mechanism, multiple cell divisions are
required in order to observe genome-wide hypomethylation, which is manifested in the daughter cell
population.
When IHN20.22 cells are induced with Dox and then treated with AzadC, there is an
obvious shift of cells from the low expressing Dim population to the high expressing Bright
population (Figure 6). The conversion of ‘dim’ cells to ‘bright’ cells by the hypomethylating drug
suggests that the repaired GFP gene in the low expressing pool is a direct result of DNA
methylation either during or soon after NHEJ repair. In the absence of AzadC, the Bright
population of cells initially decreases over 4 days then appears to stabilize (Figure 7, -AzadC). In
contrast, cells treated with AzadC displayed a clearly different trend (Figure 7, +AzadC). The drug
reverses the loss in Bright cells, probably due to the ongoing conversion of Dim cells into the Bright
pool. In either case, a few days after the damage/repair event, the proportions of cells in Bright and
Dim cell populations remain fairly stable as cells are passaged (Figure 7); however, addition of
AzadC to cells that are 24 days post-repair results in a sharp increase in the percentage of high
expressing cells (Figure 8), supporting the notion that the expression difference is likely due to postrepair methylation as opposed to an off target drug interaction during the repair process. Further,
the extent to which AzadC causes the shift from low to high GFP expression occurs is dose
dependent (Figure 9).
Since it appears that the expression classes eventually become stable, presumably due to
stable methylation marks (which are heritable) we next attempted to isolate pure populations of Dim
and Bright cells to make the analysis more tractable. Before treatment, sorted Dim cells appear as a
relatively homogenous population in a uni-modal distribution (Figure 10A) with relatively low levels
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of GFP expression (labeled as the “P1” pool). Note that while the distribution is broad, it is
nonetheless uniform with very low levels of bright GFP expressing cells (P4). Following AzadC
treatment of the Dim cell pool, a new population emerges in the high expression range (Figure 10A,
right panel “P4” pool). As with sorted Dim cells, sorted Bright cells also show a single peak of GFP
expression (Figure 10B); however, these cells are far more homogeneous (compare Figure 10A, B).
Since the Bright cell pool also shifts perceptibly to the right in the presence of AzadC (Figure 10B,
right panel, P4), we conclude that the bright pool contains cells with some degree of DNA
methylation (which is removed by AzadC) (Figure 3B). This experiment clearly evidenced the
conversion of Dim cells to Bright cells by a DNA hypomethylating drug. Live imaging reveals that
the information regulating the GFP expression level of post-repair cells is passed from parent to
daughter cells as the cells divide (Figure 11). The cause of the silencing is heritable but reversible,
pointing once more to DNA methylation as the source of the gene expression variation.
The availability of relatively pure populations of Dim and Bright cells makes it possible to
use bisulfite DNA sequencing to interrogate methylation sites before and after NHEJ. Thus, in
addition to validating the presence of epi-alleles in Dims and Brights, bisulfite DNA sequencing of
the post-repair populations makes it possible to map these epi-alleles relative to the I-Sce1 cleavage
and repair site. Bisulfite sequencing confirmed that the GFP gene is hypomethylated in sorted Bright
cells and hypermethylated in sorted Dim cells. Specifically, changes occur in regions both up and
downstream of the break site (Figure 12). Interestingly, the methylation status of CpGs in the region
directly flanking the break site is not affected by the process. This suggests a coordination of
methylation and repair proteins to affect methylation patterns in specific areas around the site of
DNA damage.
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Different DNA methylation patterns mark Recombinant from Uncut cells.
The data so far demonstrate that NHEJ is spinning out new epi-alleles that are either overwritten or completely revised from the parental (uncut) reporter DNA. Moreover, the expressability
of the repair products correlates with the percent of DNA methylation in sorted Dim and Bright
cells. The pyrosequencing analysis done thus far evaluates the average methylation levels for a single
CpG site derived from physically different molecules; however, it does not consider the relationship
between the different methylated cytosines present on the same molecule (epialleles). For this
reason, we have analyzed the composition of methylated population (heterogeneity), by counting the
number of different epialleles in the sample (haplotypes) obtained from deep sequencing analysis of
the amplicons.
The DSB region was divided into 5 segments (3 upstream and 2 downstream regions from the DSB
site, (Figure 13). Deep quantitative (Taxa, PCoA and Shannon Index) and qualitative (methylation
profiles) analysis of amplicons with the same end was carried out. The results show that
recombinant cells (both Dims and Brights) and uncut parental cells have the same types of
methylated species (un-methylated, mono, bi and tri-methylated) but with different compositions
(Figure 13). In fact, the Bright cells appear to be rich in unmethylated species compared to Dims
and Uncut in each region, confirming that high levels of GFP expression in this population are
largely unmethylated (marked by an asterisk in Fig. 5A). Moreover, Principal Coordinates Analysis
reveals that Dim and Uncut parental DNAs have a smaller euclidean distance compared to Bright
(variation 96% vs 4%), highlighting a common origin for Recombinant (i.e., NHEJ repaired) cells,
followed by a de-methylation event of the Bright cells (Figure 14). We also analyzed the diversity
index (Shannon Index) in order to evaluate the evenness of the species. Except for the region 1
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(where Bright and Uncut are much more similar to the Dims), we observe that 2 upstream regions
of DSB site (Region 2 - 3) show a gradual increase in similarity between Dims and Uncut relative to
the Bright cells (single asterisk*), while region 4 (downstream region of DSB site) shows a high
similarity between the Recombinants (Dims plus Brights) compared to the Uncut (double asterisk
**), which is lost in the region 5 (Figure 15).
Finally, we have performed a deep qualitative analysis to identify the differences between
Recombinant and Uncut (parental) cells in terms of gain or loss of methylation (Figure 16). The
differences between the percentage of Recombinant’s epialleles compared to Uncut cells show that
the Dim cells gain methylation marks in the region 1 (di-methylated epialleles), in the region 2 (mono-, diand tri-methylated epialleles), and in the region 5 (mono-, di- and tri-methylated epialleles). In contrast the
Bright cells lose methylated epialleles in these same regions. For example, in region 3, Bright cells
appear to acquire new methylation (di-methylated epialleles) while DIMS lose methylation. Both Dims
and Bright cells lose methylation (tri-, di-methylated epialleles) acquiring mono-methylated epialleles in
the region 4. Knowing the different GFP expression between the two populations, we hypothesize
that transcription may modify DNA methylation (or de-methylation) after DNA damage and NHEJ
repair, remodeling the chromatin in units with different transcriptional efficiency (and in the process
spinning out Dim and Bright cell populations).
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Discussion
Epigenetic revision as a component of tumorigenesis
Despite their involvement in so many types of cancer, the root cause of DNA
miscues is largely unknown. This study reveals a novel connection between two essential cellular
processes that has a potential role in the development and progression of cancer. Deep sequencing
analysis of post-repair DNA revealed both loss and of methylation in areas up and downstream of
the break site (Figure 6B) that is correlated with up- or downregulation, respectively. The
mechanism described here provides evidence for alterations in methylation profiles as a result of
NHEJ repair, a process which could explain the epigenetic revision that is characteristic of cancer
cells.
What is not clear is how universal and wide-spread NHEJ-mediated epigenetic revision paths
are in a tissue context. In our model system, we used a gene that is not subject to selection; however,
it stands to reason that silencing or activating a positive or negative growth-promoting gene could
produce cells that have a growth advantage relative to surrounding normal cells (8,13,64). Growth
promoting outcomes could clearly place the cell on a path toward a pre-cancerous condition. In
contrast, silencing a pro-growth gene (oncogene) could result in the loss of a cell lineage. In either
situation, tissue epistasis could be targeted with undesirable outcomes. What is intriguing is that even
when an error-prone pathway such as NHEJ regenerates wild-type sequence, there is still a good
chance for gene activation or silencing. Thus, mutating a tumor suppressor gene is functionally
equivalent to epigenetic silencing the expression of the same gene, with the same dire consequences.
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A new pathway for discovery of novel epi-therapeutic targets
Changes in DNA methylation have been shown to accumulate throughout the genome with
the progression of cancer (64-67) and have been shown to positively correlate with tumor stage (66).
Cancer cells have also been shown to acquire additional genetic mutations due to an increase in
DSBs resulting from increase reactive oxygen species production, telomeric dysfunction, genomic
instability, and replication errors (47,68). Although the increased DSB may give cancer cells a growth
advantage by providing favorable mutations in key regulatory genes, it also makes them increasingly
dependent on DSB repair in order to grow and proliferate at a high rate. If DNA methylation
revisions occur during or soon after NHEJ, as demonstrated here, further DSB repair that occurs in
rapidly dividing cancer cells may exacerbate the situation and could explain the accumulation of
inappropriately methylated or demethylated genes that is characteristic of progressing cancer. The
association of methylation revisions with tumor stage could enable their use as a cancer marker to
predict prognosis of developing cancer and to predict responsiveness to specific therapeutics (33).
Although methylation aberrations tend to accumulate with malignant progression, they have also
been shown to be present in the early stages of pre-malignancy (8,67,69). This could make them
candidates for use as a diagnostic tool for early detection of cancer cells (67,69). Further exposing
the mechanism behind the overlap of these key processes could provide new targets for therapeutics
to interfere with the progressive gain of epigenetic miscues by this mechanism and prevent tumor
progression.
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Intragenic DNA methylation and gene silencing
While methylation based gene silencing is typically associated with promotor CpG islands,
studies have also shown that intragenic methylation may affect gene expression as well. Intragenic
methylation in plant cells was shown to increase in more highly transcribed genes, presumably in an
effort to prevent aberrant transcription at other nearby sites that can result when transcription
machinery disrupts chromatin structure. Inhibition of DNA methylation in these cells caused up
regulation of genes that were methylated only in the body of the gene and not in their promoters
(70). Similar results were found in mammalian cells where intragenic methylation was shown to
decrease gene expression and facilitate compaction of chromatin that is correlated with a reduced
density of DNA polymerase II in the body of the gene (71). Further, another study concluded that a
single methylated CpG in the intron of the PMP24 gene was sufficient to silence the gene. In
addition to demonstrating the ability of intragenic methylation to silence genes, these studies suggest
a connection between methylation and reduced elongation efficiency. This supports our findings
that aberrant methylation in the body of the GFP gene causes silencing.
This also incites the idea that transcription may reshape the epigenetic landscape, a
phenomenon that has already been demonstrated to occur following DNA repair by HDR (51). It
was found that this process is mediated by Base Excision Repair (BER)-mediated demethylation
(52). Principle Coordinates Analysis presented in Figure 5B revealed that Dim cells had a closer
Euclidian distance to the original, uncut parental DNA than Bright cells. This data supports a model
where the area surrounding the site of NHEJ is first methylated and then progressively demethylated
over time with transcription, resulting in an array of epialleles with differing levels and locations of
methylated CpGs. Future work will look further into this idea.
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In summary, this study reveals a novel connection between two processes that have
important roles in cancer development and progression, NHEJ and DNA methylation. This link
provides a clue to one of the biggest unanswered question in this area of study: What causes the
epigenetic revision that is pivotal to the multistep progression of cancer? While DNA damage and
repair is stochastic, a damage event that results in epigenetic revision following repair and provides
the cell with a growth advantage could direct the cell onto a path of tumorigenesis. This could
explain why some genes exhibit inappropriate methylation patterns in some cancers but not others,
as only genes that are beneficial to that particular tissue type would confer a selective advantage.
Thus, methylation revision following DNA repair by NHEJ, the most predominant repair pathway
in animal cells, fits the criterion to be the source of epigenetic abnormalities in cancer cells and could
provide information for the development of new therapeutic strategies for preventing and stopping
this process from contributing to tumorigenesis.
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Figure 1. Reporter construct integrated into the genome of the IHN20.22 HeLa cell line.
The NHEJ reporter GFP gene contains a Pem1 intron interrupted by an adenoviral exon. Two I-Sce1 restriction sites allow the homing endonuclease
to cut the DNA and excise the adenoviral exon to produce wild-type GFP following repair by NHEJ.
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Figure 2. Generation of GFP positive cells following repair.
Cells were induced with dox for 24 hours and then the percentage of the population expressing GFP was analyzed using FACS. The circles on the
“+Dox” plot indicate two separate GFP positive cell populations with differing expression levels of GFP

24

Figure 3. Time course analysis of GFP expression.
The percentage of GFP positive cells was analyzed by FACS over the course of 9 days, either following a 24hour induction or with continuous exposure to doxycycline. The uncut cell line with no dox exposure was
also analyzed to asses basal levels of GFP expression.
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Figure 4. Live-cell imaging of GFP expression.
The onset of WT GFP expression in a single cell was observed during the 72 hours following a 24 hour Dox
induction using live-cell imaging. The arrows indicate time progression and the black circle indicates the GFP
negative cell that is GFP positive in subsequent images.
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Figure 5. Histogram of GFP+ cells after induction with dox with gating for Bright and Dim
populations.
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Figure 6. Hypomethylation by 5’Aza-2’-deoxycitidine.
IHN20.22 cells were induced with dox for 24 hours and then treated with a daily dose of 1µM AzadC for 48
hours. The percentage of cells with high (Bright) and low (Dim) GFP expression with and without AzadC
treatment were quantified using FACS histograms of GFP positive cells. The second graph is an overlay of
the histogram with (red) and without (blue) treatment with AzadC.

28

Figure 7. Characterization of the effect of hypomethylation by AzadC on the GFP expression level in
post-repair cells.
GFP expression level over the course of 7 days is compared between cells with and without AzadC treatment.
Cells were induced with dox for 24 hours and then given a daily dose of 1µM AzadC. The percentage of
Bright cells was measured using FACS on days 1, 2, 4 and 7 following initiation of AzadC treatments.
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Figure 8. The effect of AzadC treatment on post-repair cells.
The distribution of cells in each expression class was observed in the days following NHEJ repair. As
indicated by the arrow on the last graph, the cells were treated with 5µM AzadC on day 25 and then analyzed
by FACS on day 26, 27, 28, and 30.
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Figure 9. The effect of AzadC concentration on GFP expression class populations.
Cells were induced with dox for 24 hours and then given a daily dose of the indicated concentration of
AzadC for 2 days. After a 48-hour recovery, the percentage of Bright cells was determined using FACS. The
fold increase in the percentage of bright cells is shown.
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A

Dim

Dim treated with AzadC

B

Bright

Bright treated with AzadC

Figure 10. Treatment of sorted populations with AzadC.
Dim (A) and Bright (B) populations were sorted using FACS and then the sorted populations were treated
with a daily dose of AzadC for 48 hours. The level of GFP expression was measured using FACS. The blue
line in (B) indicates the median of the Bright peak.
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Figure 11. Live-cell imaging of Dim and Bright cells.
Live-cell imaging was used to observe the origination and propagation of cells with Dim and Bright
expression of GFP during the 72 hours following a 24 hour dox induction. The arrow indicates the
progression of time.
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Figure 12. Bisulfite Sequencing of sorted Dim and Bright cells.
Next-Generation Sequencing of bisulfite converted DNA was used to determine the methylation patterns of
the area around the site of repair in sorted Dim and Bright cell populations as well as uncut IHN20.22 cells.
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Figure 13. Profile composition of Bright, Dim, and Uncut cell populations.
Epialleles profiles obtained from the analysis of the methylation of each amplicons were subjected to alpha and beta diversity (Qiime). Compositions are
grouped by number of methylated CpGs for the five regions adjacent to the DSB. “0 (red color = un-methylated)", "1 (blue = mono-methylated)", "2
(orange = di-methylated)" and "3 (green = tri-methylated)" represent the percent to class of methylation.
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Figure 14. Principal coordinate analysis of Bright, Dim and Uncut populations.
Epialleles profiles obtained from the analysis of the methylation of each amplicons were subjected to alpha and beta diversity (Qiime). In the X and Y
axes are represented, respectively, the first and the second components (PC1 and PC2) with the amount of variance in the samples explained by these
components, included in brackets. The first principle component represents the highest variance, and the total variance of the samples is the cumulative
sum of that described by each of the axes.
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Figure 15. Shannon diversity index between Bright, Dim and Uncut populations.
Epiallele profiles obtained from the analysis of the methylation of each amplicons were subjected to alpha and beta diversity (Qiime). In the X and Y
axes are represented, respectively, “number of sequences for sample” and “Rarefaction measure (species richness)” for Shannon Index.
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Figure 16. Gain or loss of methylation in Bright and Dim populations compared to the Uncut population.
Epialleles profiles obtained from the analysis of the methylation of each amplicons were subjected to alpha and beta diversity (Qiime).
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Table 1. Summary table of methylated profiles for region.
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Region 1
profiles

Region 5
UNCUT

DIMS

BRIGHT

45.13

0
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5.61
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2
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1
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2

0

0

0
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1

2.20

3.04
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2
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1
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3
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Table 2. List of bisulfite sequencing primers

REGION

PRIMER

SEQUENCE

1
1
2
2
3
3
4
4
5
5

F'
R'
F'
R'
F'
R'
F'
R'
F'
R'

5’-AGGTTAGTTTGGGTTATATGAGAGTTTG-3’
5’-TTTCAAACTACCCCATATAACATCTAACC-3’
5’-TGGTAAGGGATTTTGTAGATTATTGGATTTAG-3’
5’-CTACTATACTCACCCATTATTCTAAAAACAC-3’
5’-AGGTTGTATTTTATTTTTATAGTTAGGTTTGTTTAGG-3’
5’-ATCTAAAAATACATTAAAAAATCCTCTTTCCCCTTC-3’
5’-GTGATTATGGTTTTGTTTTTTTTTTTGGAATTGT-3’
5’-CTAACACTCCCTACTTAATAAAAACTCC-3’
5’-GGAGTTTTTATTAAGTAGGGAGTGTTAG-3’
5’-CCCCATAAAAACCCACAATATTTCAAATC-3’
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CHAPTER THREE:

Introduction
Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinomas (HNSCCs) are squamous cell cancers originating
in the lip and oral cavity, nasopharynx, oropharynx, hypopharynx, or larynx. The etiologies of
HNSCC are divided into two groups corresponding to the two major risk factors for this type of
cancer: exposure to alcohol and tobacco and infection with human papillomavirus (HPV). Smoking
increase the risk of HNSCC 5 to 25-fold (72) and the risk is even higher when habitual smoking and
alcohol use are combined. Over the last decade, there has been a decrease in smoking- related
HNSCCS that is correlated with a decrease in the use of tobacco products. This decline is occurring
congruently with an increase in HPV-positive HNSCC incidence, particularly in younger individuals
(72-75). The differing causations of HPV-positive and HPV-negative HNSCC essentially produces
two diseases with two distinct pathogeneses. In addition to having different biological and clinical
phenotypes, HNSCCs that are HPV-positive are associated with a better prognosis than those that
are HPV-negative (76,77).

The role of DNA methylation in HNSCC
As discussed in chapter two, changes in DNA methylation patterns are seen across many
different type of cancer and HNSCC is no exception. The extent of aberrant methylation patterns in
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HNSCC have been recently been shown to have predictive value in determining patient prognosis
(78) and is correlated with progression of the disease (79).
While both HPV-negative and HPV-positive HNSCCs exhibit changes in DNA methylation
patterns, studies have shown that methylation patterns are different between the two both in a
global and site-specific manner (76,80-83). HPV-positive tumors tend to have greater levels or CpG
methylation while HPV-negative tumors tend to exhibit global hypomethylation (76,80-82,84). It has
been shown that HPV viral oncoproteins can cause changes in DNA methylation and upregulation
of DNMTs (85,86) and may interact with DNMTs (87) or be involved in the upregulation of
DNMTs by interacting with other regulators like p53 (88,89) and RB1 (90). While this could explain
some of the hypermethylation seen in HPV-positive tumors, other mechanisms contributing to
hypomethylation and to methylation changes in HPV-negative cancers have not yet been identified.

Circulating oncogenic agents in serum
Studies have also demonstrated the ability of serum from cancer patients to generate
tumorigenic phenotypes in treated cells in culture (91-93). This can occur by horizontal gene transfer
from circulating, cell-free DNA (93,94) or by the uptake of extracellular vesicles (EVs) that are
released into circulation by cancer cells (95-98). Extracellular vesicles, or exosomes, are membrane
bound vesicles that may contain membrane or cytosolic proteins, lipids, or nucleic acids for use in
intercellular signaling (99). Released by both healthy and cancer cells, exosomes are found in many
different body fluids including urine, breast milk blood serum and plasma, amniotic fluid, ascites,
semen, and saliva (95,99). Cancer cells use this mechanism to package and deliver oncogenic
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proteins (100,101), mRNA and miRNA (100,102,103), or DNA (96) that are capable of causing
malignant transformation of recipient cells or facilitate cancer progression and metastasis (95).
Because serum circulates throughout the body and is easily accessible in a clinical setting, it is
often examined for the presence of biomarkers that are associated with various disease states.
Differing protein (104-107) and RNA(108,109) profiles between healthy individuals and patients
with different types and stages of cancer have been identified and found to have diagnostic or
prognostic value (110). In addition, epigenetic changes, such as abnormal methylation patterns, have
been identified in cancer-associated DNA from blood serum from cancer patients and have been
used as biomarkers for detection, diagnosis, and prognosis of many different types of cancer (111113).
Circulating blood serum may contain a mixture of DNA, RNA including miRNA, and
protein, all of which may participate in epigenetic processes. In this work, we investigate whether
circulating oncogenic materials in the blood serum of cancer patients, in addition to being useful as
diagnostic tools, may contribute to tumorigenesis and progression by causing changes in the normal
patterns of epigenetic regulation in distal cells, specifically by altering DNA methylation patterns.

Materials and Methods
Generation of the Dim HeLa cell line
Following induction of DNA damage and repair, NHEJ reporter HeLa cells were sorted
based on their fluorescence intensity into Dim and Bright populations (114). Hypermethylation of
the Dim cells was confirmed using bisulfite sequencing of an area of the integrated GFP gene.
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Human blood serum collection
Serum from 71 HNSCC patients aged between 40 and 88 (Mean age 62 years, STDEV= 9.2)
with varying tumor grades and locations in the oral cavity, oropharynx, and larynx were used in this
study along with serum from 10 samples from healthy patients aged between 46 and 59. Serum was
collected prepared in the Department of Head and Neck Surgery, Greater Poland Cancer Center
before surgical treatment. The Institutional Review Board of University of Medical Sciences in
Poznan approved the study, and informed consents were obtained from all patients. Blood samples
were collected in BD Vacutainer Serum Separation Tubes, incubated for 15 minutes at room
temperature to allow coagulation, and centrifuged at 1300 g for 10 minutes. The serum supernatant
was transferred to new tubes, centrifuged at 16,000 g for 15 minutes to remove any residual cells and
debris, and stored at −80°C (115).

Cell culture
HeLa cells were grown in RPMI basal medium with L-glutamine and supplemented with
10% FBS and 1% penicillin-streptomycin. Cells were grown at 37C at 5% CO 2.

HNSCC serum treatments
HeLa cells were plated in 96-well plates (Corning) at low density and allowed to attach for
several hours. Medium was then removed and replaced with freshly prepared medium containing
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10% human serum and no FBS. Cells were allowed to grow for 72 hours before lifting for FACS
analysis.

AzadC treatment
Fresh AzadC was prepared by dissolving in DMSO at a concentration of 10mM. HeLa cells
were plated in 96-well plates at low density and allowed to attach for several hours. Cells were given
a daily dose of AzadC at a final concentration of 1 M for 48 hours and then lifted for FACS
analysis.

FACS analysis
Dim cells were trypsinized and centrifuged at 1000xg for 5 minutes and then re-suspended in
PBS at a density of 10 6 cells/mL Cells were run on an Accuri Flow Cytometer. Live cells were
selected using a plot of SSC-A vs FSC-A and then a histogram of FL1-A was used to identify and
gate cells in the Dim population. Gating and statistical analysis was done using FlowLogic software.

Exosome depletion
Media was prepared using 10% human serum from either HNSCC patients or healthy
individuals and placed in 1.5mL ultracentrifuge tubes (Beckman Coulter) and spun at 120,000 x g in
a fixed angle rotor at 4C using a Beckman TLX 120 tabletop ultracentrifuge for 4 hours. The
supernatant containing media and serum was removed from the pelleted exosomes and then remixed together before it was added to the cells.
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RNase A digestion
Media was prepared using 10% human serum from either HNSCC patients or healthy
individuals and then digested with 100 g/mL RNase A (Thermoscientific) for 1 hour at 37C
before it was added to the cells.

Proteinase K digestion
Human serum was digested in 200ng/L Proteinase K (Promega) overnight at 37C.
Proteinase K was deactivated by incubation in 200M phenylmethylsulfonyl fluoride (PMSF)
(ThermoScientific) before preparing medium with digested serum.

Human serum fractionation
Human serum was filtered using Amicon  Ultra-0.5mL centrifugal filters. Serum was first
filtered through a 30 kDa filter, then the filtrate was filtered through a 10 kDa filter, and then that
filtrate was passed through a 5 kDa filter to yield 4 fractions containing different protein size ranges.
Media was prepared using 10% of the indicated fraction of serum.

Statistical analysis of fluorescence intensity changes
Mean fluorescence intensity and percent Dim values for cells treated with healthy and caner
serum were subjected to a two-tailed t-test with a 95% confidence interval. Graphed results are
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indicated as mean  standard error of the mean (SEM). Statistics and graphs were generated using
Prism 5 software (GraphPad).

Results
Circulating hypomethylating agents in HNSCC serum
In order to study the effects of HNSCC patient serum on DNA methylation, we used a GFP
reporter cell line that has a methylated GFP gene. This reporter line, which we have named “Dim”
was generated during our previous studies where we determined that DNA methylation changes
occur following repair by NHEJ (114). Since we have confirmed that the GFP gene in these cells is
methylated and that hypomethylation causes an increase in their GFP expression, we can use these
cells as reporters for DNA hypomethylating agents.
The Dim HeLa cell line express GFP moderately, appearing as a uniform peak on FACS
histograms (Figure 17). Treatment with serum from HNSCC patients causes a populations of Dim
cells to increase their expression of GFP. This is visualized on FACS histograms by a shift of cells
from the gated “Dim” population into a “Bright” expression class (Figure 18). Treatment with
serum from a control group of healthy individuals did not produce the same response (Figure 19).
In order to generate a standard for comparison of what FACS histograms of the Dim cells look like
when GFP becomes hypomethylated, the cells were treated with, 5-Aza-2’-deoxycytidine (AzadC), a
drug with known hypomethylating actions that have led to its approval by the FDA for treatment of
myelodysplastic syndrome (24). The shift from Dim to Bright cells following AzadC treatment
(Figure 10, A) is unique to the hypomethylating drug and is not seen following treatment with other
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types of drugs or sera (data not shown). The similarity in responses of Dim cells to HNSCC patient
serum and to the hypomethylating drug indicate that there is some factor in HNSCC patient serum
that also acts as a hypomethylating agent.
Unlike their response to normal human serum, the response of Dim cells to serum from
different HNSCC patients was heterogeneous. Serum from some patients caused a significant shift
from the Dim to the Bright GFP expression class (Figure 18) while the effect of serum from other
patients was not as pronounced (Figure 20). Serum that caused greater shifts were designated as
“Responders” while those effecting only small shifts were classified as “Partial Responders”. Still
others had little to no effect on GFP expression and were termed “Non-Responders” (Figure 21).
There was a positive correlation of the expression level of GFP determined by qPCR and the
fluorescence intensity measured by FACS (r=0.37, p=0.04), indicating that the shift seen in FACS
data was in fact due to changes in expression of the GFP gene. Although there was diversity in the
response of Dim cells to the serum from different HNSCC patients, the difference in their overall
response to serum from cancer serum versus healthy human serum was statistically significant
(Figure 22). The percent of the cells contained in the Dim category was decreased and the mean
fluorescence intensity was increased in cells treated with cancer serum compared to those treated
with healthy human serum. Thus, serum from HNSCC cancer patients, but not from healthy
individuals, has the capacity to induce hypomethylation in treated cells. Further, continuous serum
exposure was required to maintain the GFP expression change. When cells were treated with human
serum and then allowed to recover in normal culture medium containing FBS, the cells ret urned to
their original expression class (Figure 23).
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Identifying the type of hypomethylating agent in HNSCC serum
Although it has been demonstrated that exposure to HNSCC patient serum alters
methylation profiles in treated cells compared to normal human serum, it is still unclear what
elements are contained in the serum that are causing these effects. In order to identify the causative
agent, we used a knockout method by removing specific types of serum components individually
and then using serums classified as “Responders” as a screen to measure the ability of the treated
serum to generate the same hypomethylation response. We first hypothesized that miRNA
contained in the serum may be responsible. To investigate this, we pre-treated serum with RNase A
before treating the cells. This treatment had no effect on the serums’ hypomethylating actions
(Figure 24, Figure 25). Since the RNA contained in serum is known to be contained in exosomes
(95) which would prevent their exposure to the RNase A treatment, we next depleted the serum of
exosomes prior to cell treatment. As with RNase A treatment, exosome depletion did not hinder the
hypomethylating effects of HNSCC patient serum (Figure 26, Figure 27).
Next, we sought to determine if the source of the methylation changes was a protein, so we
digested the serum with Proteinase K prior to treating the cells. Removal of protein from the serum
ablated the shift from low GFP expression to high GFP expression that was previously observed
when Dim cells were treated with HNSCC patient serum (Figure 28). Since the difference in mean
fluorescence intensity between HNSCC serum treated Dim cells with and without Proteinase K
treatment is statistically significant (Figure 29), these data identify the hypomethylating effector as a
protein contained only in HNSCC serum or in different quantities than normal human serum.
To obtain more information about what protein is causing the hypomethylating effects of
HNSCC patient serum, we filtered the serum into 4 fractions based on protein size so that each
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fraction contains proteins within a specific size range. Treatment of Dim cells with the fraction
containing proteins that are greater than 30 kDa caused a shift in GFP expression that appears even
more pronounced than that caused by the total serum, while fractions containing only smaller
proteins produced little or no change in GFP expression (Figure 30). These results classify the
unknown protein as being greater than 30 kDa. Since 10% serum was used in each treatment, the
fractions contained concentrated amounts of proteins in their respective size range. The increased
concentration of the hypomethylating protein in the greater than 30 kDa fraction caused more
hypomethylation in Dim cells than the total serum with all proteins.
To clarify if the epigenetically active protein was also contained in healthy human serum but
in smaller amounts, we filtered the serum from a healthy individual into two fractions, one
containing proteins greater than 30 kDa and one containing proteins smaller than 30 kDa. If the
protein is also contained in this serum, we would expect that concentration of the proteins that are
over 30 kDa would concentrate this protein enough to produce a change in GFP expression of the
dim cells. Neither fractions from this serum produced a shift in GFP expression in Dim cells (Figure
31), confirming that the hypomethylating protein is present only in the serum from the cancer
patients.

Discussion
Cancer cells may induce epigenetic changes in distant cells
The importance of epigenetic changes in cancer progression has already been discussed, but
the potential for cancer cells to broadcast epigenetic changes to cells in other areas of the body has
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critical implications on their metastatic potential. This gives cancer cells the power to incite
carcinogenic processes in distant, healthy cells and facilitate progression of the disease. Further,
although the model presented in this paper reports that HNSCC patient serum can cause
hypomethylation in exposed cells, it does not exclude the possibility of other factors in serum that
may affect epigenetic regulation in other ways such as DNA hypermethylation or changes in histone
marks.
Studies have suggested a correlation between cancer stage and serum levels of epigenetic
regulators like DNMT1 and HDAC1 (116,117), however, to our knowledge, this is the first study
demonstrating epigenetic change as a result of circulating, cancer-associated proteins. This finding is
especially interesting given our limited knowledge of how DNA demethylation occurs in animal cells
despite the fact that, as previously mentioned, hypomethylation frequently contributes to cancer
progression by activating oncogenes (8). HNSCCs, specifically, have been shown to have increased
levels of global hypomethylation that correlate with smoking and tumor stage (118) and to be more
pronounced in HPV-negative tumors (81). In fact, studies have demonstrated a correlation between
smoking and DNA hypomethylation independently of HNSCC (119,120).

Mechanisms of DNA demethylation
DNA demethylation may occur passively as a result of a failure of DNMTs to propagate
methylation marks to daughter DNA strands during replication, or actively by conversion of 5 methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) through the enzymatic activity of the
ten-eleven translocation (Tet) family of dioxygenases. 5hmC is then further oxidized by Tet to form
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) which can then be excised and replaced with
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cytosine by base excision repair (BER) (121,122). Studies have demonstrated that Tet enzymes are
often mutated or downregulated in cancer which can contribute to hypermethylation that is
characteristic of cancer cells (123-125). This does not explain the aberrant hypomethylation that is
seen throughout the development of cancer and that is highlighted in this study.
Another explanation for progressive demethylation during tumorigenesis is alterations in the
structure of chromatin which makes the DNA more susceptible to demethylation. It is widely
understood that DNA methylation contributes to the condensation of chromatin and thus local
inactivation of genes, however less known are studies that have shown that this process occurs
bilaterally. Deacetylation of histones causes changes in chromatin structure to an inactive state that
protects DNA from demethylation, while deacetylation opens chromatin and allows for demethylase
activity. This is supported by the demonstrated ability of inhibitors of histone deacetylases (HDACs)
and histone acetyltransferases (HATs) to cause DNA hypomethylation (121,126-128).

Potential identities of the unknown protein
While the specific identity of the hypomethylating protein discovered in this study remains
unresolved, fractionation of the serum by protein size allowed for smaller growth factors and
signaling molecules to be eliminated as candidates. While it is possible that the serum contains a
protein that is directly responsible for enzymatic demethylation of DNA, it is more likely that it
contains a protein that is causing an indirect demethylation effect due to interaction with other
cellular components. For example, the protein could affect histone acetylation which could in turn
alter DNA methylation patterns. Alternatively, the protein could affect the expression, processing,

52

or stability (129,130) of miRNAs that are involved in epigenetic mechanisms (131,132) of gene
expression or in regulation of epigenetic proteins.
Future studies will be aimed at uncovering the identity of the circulating, cancer-associated
hypomethylating protein contained in HNSCC patient serum. In addition to providing a potential
target for diagnostics, a biologically active, circulating protein with tumorigenic effects could be an
ideal therapeutic target to interrupt the metastatic progression of cancer.
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Figure 17. FACS analysis of Dim HeLa cells grown in FBS.
Histogram of GFP expression of the Dim HeLa cell line under normal culture conditions with gated “Dim”
population.
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Figure 18. FACS of Dim HeLa cells treated with HNSCC patient serum: Responders.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with HNSCC patient
serum. Cells in the “Dim” expression are gated as in Figure 17 and numbers indicate the serum sample
number. These serums are called “Responders” as they produced the biggest shifts in GFP expression
compared to other serums.
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Figure 19. FACS histograms of Dim HeLa cells treated with normal human serum.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with healthy human serum.
Cells in the “Dim” expression are gated as in Figure 17 and numbers indicate the serum sample number.
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Figure 20. FACS histograms of Dim HeLa cells treated with HNSCC patient serum: Partial
Responders.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with HNSCC patient
serum. Cells in the “Dim” expression are gated as in Figure 17 and numbers indicate the serum sample
number. These serums are called “Partial Responders” as they produced a significant shift in GFP expression
but not as pronounced as those in the “Responder” category.
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Figure 21. FACS histograms of Dim HeLa cells treated with HNSCC serum: Non-Responders.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with HNSCC patient
serum. Cells in the “Dim” expression are gated as in Figure 17 and numbers indicate the serum sample
number. These serums are called “Non-Responders” as they produced little or no shift in GFP expression.
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Figure 22. Statistical analysis of the effect of normal human and HNSCC patient serum on GFP
expression in Dim HeLa cells.
The percentage of cells in the Dim expression class (A) (p=0.0015) and the mean fluorescence intensity (B)
(p=0.0018) was compared for cells treated with HNSCC patient serum (n=68) and normal human serum
(n=10).
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Figure 23. Treatment with human serum followed by recovery in FBS.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with normal human serum
(A) or HNSCC patient serum (B) for 72 hours (graph to the left of each arrow) followed by recovery in
normal media with FBS for 6 days (graph to the right of each arrow). Serum sample number is indicated in
the bottom left corner of each graph.
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Figure 24. Degradation of RNA in HNSCC serum.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with normal human serum
(A) or HNSCC patient serum (B) with and without digestion with RNase A. Serum sample number is
indicated in the bottom left corner of each graph.
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Figure 25. Statistical analysis of the effect of RNA degradation on the hypomethylating effects of
HNSCC patient serum.
The mean fluorescence intensity of Dim cells after treatment with serum with or without RNase A digestion.
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Figure 26. Treatment of Dim HeLa cells with exosome depleted human serum.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with normal human serum or HNSCC patient serum with
and without exosome depletion. Serum sample number is indicated in the bottom left corner of each graph.
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Figure 27. Statistical analysis of the effect of exosome depletion on the hypomethylating effects of
HNSCC serum.
The mean fluorescence intensity of Dim cells after treatment with serum with or without exosome depletion.
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Figure 28. Degradation of protein in human serum.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with normal human serum
(A) or HNSCC patient serum (B) with and without digestion with Proteinase K. Serum sample number is
indicated in the bottom left corner of each graph.
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Figure 29. Statistical analysis of the effect of protein degradation on the hypomethylating effects of
HNSCC serum.
The mean fluorescence intensity (p=0.0001) was compared for cells treated with HNSCC patient serum
(n=15) with and without Proteinase K treatment.
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Figure 30. Filtration of HNSCC serum into fractions with differing protein sizes.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with total HNSCC patient
serum and with serum fractions that were filtered based on protein size. Rows contain data for different
serum samples and columns contain data for fractions of different protein size ranges. Serum sample number
is indicated in the bottom left corner of each graph and protein size range is indicated at the top of each
column.
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Figure 31. Filtration of healthy human serum into fractions with differing protein sizes.
FACS histograms of the GFP expression levels of Dim HeLa cells after treatment with total healthy human
serum and with serum fractions that were filtered based on protein size. Serum sample number is indicated in
the bottom left corner of each graph and protein size range is indicated at the top of each graph.
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CHAPTER FOUR

Introduction
MiRNAs in cancer
MicroRNAs are small, non-coding RNA molecules that are involved in gene regulation.
After being transcribed, primary miRNA (pri-miRNA) transcripts are processed into pre-miRNA
hairpin structures before being cleaved into short, dsRNA fragments. Finally, one strand of the
fragment is then degraded to form the mature miRNA.
MiRNAs participate in regulation of gene expression by forming RNA-induced silencing
complexes (RISCs) that target complementary sequences on mRNA and either inhibit translation or
cause degradation. Further, miRNAs can contribute to tumorigenesis either by upregulation of a
miRNAs targeting tumor suppressor genes or downregulation of miRNA targeting oncogenes (133).
For example, miR124a is frequently down regulated in several cancer types including colon, breast,
and lung carcinomas as well as some leukemias and lymphomas. Because this miRNA is a negative
regulator of CDK6, down regulation caused by hypermethylation results in increased levels of
CDK6 which in turn facilitates inactivation of RB1 via phosphorylation (141). MiRNAs have also
been shown to regulate epigenetic processes by targeting DNMTs, and histone methylating EZH2
complexes (142-144). Aberrant miRNA expression can result from chromosomal deletions,
mutations affecting genes involved in miRNA processing, or by epigenetic mechanisms that affect
miRNA expression (134). DNA methylation and chromatin remodeling processes can cause
dysregulation of miRNA in the same way as they do with gene encoding transcripts (135-137) as
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evidenced by the ability of HDAC inhibitors (138,139) and hypomethylating drugs (140) to induce
changes in miRNA expression. This demonstrates interdependent regulation between the
mechanisms.

miRNAs in HNSCC
Studies have demonstrated differing miRNA expression profiles between cancer tissue and
adjacent healthy tissue in HNSCC patients (145), between serum from HNSCC patients and serum
from healthy individuals (115) and between serum collected from HNSCC patents before and after
treatment (146). Further. several of these miRNA have been shown to have diagnostic or prognostic
value (147). As we have discussed, blood serum contains circulating factors that can cause malignant
transformation in distal cells and we have already demonstrated the ability of HNSCC patient serum
to epigenetically alter gene expression (Chapter 3). In this study we investigate the potential for
cancer serum to effect miRNA regulation in exposed cells.

Materials and Methods
Human blood serum collection
Serum was collected prepared in the Department of Head and Neck Surgery, Greater Poland
Cancer Center before surgical treatment. The Institutional Review Board of University of Medical
Sciences in Poznan approved the study, and informed consents were obtained from all patients.
Blood samples were collected in BD Vacutainer Serum Separation Tubes, incubated for 15 minutes
at room temperature to allow coagulation, and centrifuged at 1300 g for 10 minutes. The serum
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supernatant was transferred to new tubes, centrifuged at 16,000 g for 15 minutes to remove any
residual cells and debris, and stored at −80°C (115).

Cell culture
HeLa cells were grown in RPMI basal medium with L-glutamine and supplemented with
10% FBS and 1% penicillin-streptomycin. Cells were grown at 37C at 5% CO 2.

HNSCC serum treatments
HeLa cells were plated in 24-well plates (Corning) at low density and allowed to attach for
several hours. Medium was then removed and replaced with freshly prepared medium containing
10% human serum and no FBS. A total of 11 serum samples were used, 7 from HNSCC patients
and 4 from healthy individuals. Cells were allowed to grow for 72 hours before extracting RNA.

miRNA Extraction
Total RNA was extracted from a confluent well of a 24-well plate of serum-treated cells
(n=11) using RNeasy Universal Plus Mini Kit (Qiagen) according to the manual with option to
include miRNA. MiRNA was extracted from 200 L serum using miRNeasy Serum/Plasma kit
(Qiagen) according to manual. RNA concentration and purity was determined using a Gen 5 plate
reader (EpochTM Mircoplate Spectrophotometer, BioTek, Winooski, VT, USA).
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miRNA library preparation and sequencing
Libraries for miRNA sequencing were prepared from RNA from serum and serum treated
cells using NEBNEXT Small RNA Library Prep Set for Illumina (New England Biolabs). Libraries
were prepared according to the manufacturer’s protocol using a 6% Polyacrylamide gel for size
selection. Each sample was given a unique index primer and then all serum samples and all cell
samples were pooled. The quantity and quality of miRNA libraries was determined using
BioAnalyzer and RNA Nano Lab Chip Kit (Agilent Technologies, Santa Clara, CA, USA), and the
samples were combined in a single microcentrifuge tube and submitted to sequencing on a HiSeq
2500 instrument (Illumina Inc.).
Sequencing data was analyzed using sRNAtoolbox (148) for alignment and quantification of
miRNA libraries and using EdgeR (149) for statistical analyses of differentially expressed miRNAs.
MiRNAs with a FDR<0.05 and FC>1.3 were considered as up-regulated; and FDR<0.05 and
FC<0.70 were considered as down-regulated. R (3.2.2) software and the Bioconductor package
DESeq (1.2.0) were used for unsupervised hierarchical clustering for the 50 most expressed miRNAs
(150) and miRNA gene families were identified using miRBase (151).

Target and Pathway analysis of miRNA-seq
DIANA-mirPath (v.3) was used for gene ontology (GO) analysis of biological processes and
KEGG molecular pathways (152,153) using validated gene interactions of the differentially regulated
miRNAs using Tarbase v7.0 database (154) considering P values lower than 0.05 as significant for
pathway and GO Terms enrichment. Only KEGG pathways with at least 9 targeted genes targeted
by at least 6 miRNAs were reported.
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Real Time PCR
Cells were seeded in 24-well plates in normal culture medium with FBS. After cells attached,
media was removed and replaced with freshly prepared media supplemented with 10% human
serum in place of FBS and allowed to grow for 72 hours. Cells were lifted and RNA was extracted
using RNeasy Plus Universal Mini Kit (Qiagen) according to kit manual. RNA concentration and
purity was determined using a Gen 5 plate reader (EpochTM Mircoplate Spectrophotometer,
BioTek, Winooski, VT, USA).
RNA was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad) according to kit
protocol using 40 L reaction volumes and then samples were diluted to 80L. Reactions were set
up in a MicroAmp® Fast Optical 96-Well Reaction Plate (Applied Biosystems) with 2 L of cDNA,
0.2 L each of forward and reverse primer, 12.6 L of nuclease free water, and 5 L of Fast SYBR
Green Master Mix (Applied Biosystems) per well. Quantitative PCR was performed using a 7900
HT Fast system (Applied Biosystems) for polymerase activation at 95C for 20 seconds followed by
45 cycles of 1 second denaturation at 95C and 20 second extension at 62C. Primer sequences are
listed in Table 6. List of primers used to determine relative gene expression.
Beta-2-microglobulin (B2M) was used as a housekeeping gene to normalize qPCR data.
Relative gene expression was calculated using the following equation: 2 A-B/2 C-D (A=Ct value of the
gene of interest in the first control (healthy human) sample, B=Ct value of the gene of interest in
each sample, C=Ct value of B2M in the first control (healthy human) sample, D=Ct value of B2M
in each sample. This gives the first control (healthy human) sample a relative expression of 1 and a ll
other samples are calculated in relation to this sample. The results of healthy individual group were
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averaged and results of other samples were divided by this average to give the fold change in
expression of genes of interest in cells treated with cancer serum compared with cells treated with
healthy human serum (155).

Statistical analysis of relative gene expression
Relative expression of genes of interest for cells treated with healthy or cancer serum were
subjected to a two-tailed t test with a 95% confidence interval and graphed with mean  standard
error of the mean (SEM) using Prism 5 software (GraphPad).

Results
HNSCC patient serums alter the miRNA profile of treated cells
In order to investigate the effects of cancer-associated circulating factors on cells in culture,
we treated HeLa cells with serum from HNSCC patients and from healthy humans. NextGeneration sequencing of miRNA reveals that serum from HNSCC patients induces a different
miRNA expression profile than the serum form healthy individuals. We detected a total of 377
miRNA expressed in HeLa cells and found a total of 16 miRNAs that were differentially expressed
(Table 3): 12 were down-regulated and 4 were up-regulated in cells that were treated with cancer
serum compared to cells treated with healthy human serum.
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Key pathways are targeted by differentially expressed miRNAs
Tarbase did not contain interaction data for four of the differentially expressed miRNA that
were identified, but analysis of the gene ontologies (GO) (Table 4) and pathways (Table 5) targets of
the other 12 miRNA reveal that these miRNA target genes involved in key biological processes. In
addition to several targeted cancer pathways, other cancer-related processes such as focal adhesion,
cell cycle and apoptosis, and critical signaling pathways were identified. These data expose the
potential ability of HNSCC patient serum to affect expression of genes in key cellular pathways by
altering levels of regulating miRNAs.

Other critical genes are affected by exposure to HNSCC serum
In order to relate the differentially expressed miRNA to gene expression, we performed
quantitative PCR to measure mRNA levels of some critical genes involved in cancer. A total of 14
genes were tested and 5 were found to have significantly reduced expression (p<0.05) in cells that
were treated with cancer serum compared with those treated with serum from healthy individuals
(Figure 32). This further demonstrates the ability of HNSCC serum to alter the expression of
cancer-related genes when introduced to cells.
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Discussion
Differentially expressed miRNAs are involved in cancer pathways
The miRNAs identified in this study interact with proteins that are known to be involved in
oncogenic processes including proliferation, survival, and angiogenesis (Figure 33), and many have
been shown to be dysregulated in cancer. Dysregulation of proteins involved in the regulation of
apoptosis can have oncogenic consequences as evidenced by the many cell cycle regulating proteins
that are either tumor suppressors or oncogenes. One of these proteins that is frequently mutated or
dysregulated in cancer is p53, which acts as a guardian of the DNA damage cell cycle checkpoint and
is responsible for initiating apoptosis when damage cannot be repaired. P53 is a vital tumor
suppressor demonstrated to play a major role in head and neck cancer as well as in other types of
cancer (156). In this study, we identified MDM2 as a target of miR-32-5p (Figure 33), which we
found to be downregulated in cells treated with cells treated with HNSCC serum compared with
those treated with healthy serum. This interaction is supported by studies demonstrating the ability
of miR-32 to cause accumulation of the tumor suppressor p53 by facilitating degradation of MDM2
(157). Further, Sirt1, a target of miR-128-3p and miR-32-5p, also deacetylates p53 thereby inhibiting
its transcriptional activity (162), so reduced expression of these miRNA could facilitate p53
inhibition by increasing Sirt1 expression. Notably, we also found that exposure to HNSCC serum
resulted in decreased p53 expression.
Two other miRNAs found in this study to be downregulated by HNSCC patient serum
exposure, miR-212-5p and miR-132-5p, also target proteins involved in cell cycle regulation. MiR212-5p targets CCND1 and miR-132-5p targets Bcl2 (Figure 33). The protein product of CCND1,
cyclin D1, cooperates with other proteins facilitate cell cycle progression from G1 to S phase while
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Bcl2 inhibits apoptosis by blocking the activity of pro-apoptotic proteins like Bax, Bak, and p53.
MiR-132 and miR-212 are formed by differential processing of the same pri-miRNA, and
upregulation of this gene cluster was shown to increase apoptosis as well as downregulate cyclin D1
and induce cell cycle arrest (158).
Mir-128 has been shown to be downregulated in many types of cancer and has been shown
to act as a tumor suppressor in HNSCC specifically. Overexpression of miR-128 in HNSCC cell
lines inhibited cell growth and downregulated anti-apoptotic proteins including MDM2, Bcl2, and
NFkB (159). MCL1, another anti-apoptotic member of the BCL2 family, is a target of miR-32-5p,
and overexpression of miR-32 was shown to induce apoptosis (160). MiR-135-5p, one of the
miRNAs found to be upregulated in cells treated with HNSCC, targets the tumor suppressor APC
and has been shown to promote cell growth in colorectal cancer (161).
We found that SLC2A1, a target of miR-30c-2-3p, was downregulated in cells treated with
cancer serum but not with normal serum. Although the other downregulated genes identified in this
study were not identified as direct targets of the differentially expressed miRNA, they could be
indirectly affected by other genes that are targeted. Several of the miRNAs identified target genes
that are involved in regulating gene expression such as transcription factors and histone modifiers,
potentially enabling them to pleiotropically alter gene expression in the treated cells.

HNSCC serum promotes a tumorigenic expression profile in exposed cells
In summary, 16 miRNAs were found to be differentially expressed in cells treated with
HNSCC patient serum compared with cells treated with healthy human serum. These miRNAs are
involved in essential cellular processes that dysregulated in cancer cells. Further, the serum altered
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the expression of several cancer-related genes. While other studies have demonstrated differences in
miRNA expression between healthy and cancer tissue in HNSCC as well as in serum from HNSCC
patients compared with serum from healthy individuals, this study goes further to demonstrate the
ability of cancer serum to alter the expression of genes and miRNA in exposed cells. This concept
could have significant impact on the study of metastatic cancer as it reveals the ability of cancerassociated factors in circulation to affect the expression of genes and regulatory elements in distal
cells in favor of tumorigenesis. Further, this could contribute to the systemic effects that cancer has
on patient health.
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Table 3. List of miRNA differentially expressed between cells treated with healthy HNSCC patient
serum and with normal human serum.

miRNA

HEALTHY 1, 2

CANCER1, 3

FC4

P-VALUE

FDR5

Down-regulated
hsa-miR-216b-5p6
hsa-miR-128-3p6
hsa-miR-216a-3p
hsa-miR-4443
hsa-miR-24-1-5p
hsa-miR-212-5p
hsa-miR-424-3p
hsa-miR-4483 6
hsa-miR-132-5p
hsa-miR-216a-5p6
hsa-miR-32-5p
hsa-miR-5100

1945.6  753.8
6633.9  762.8
317.0  130.3
50.9  25.6
38.7  8.6
225.6  44.9
169.9  51.3
38.9  13.1
557.4  61.2
169.8  69.6
607.1  71.7
400.9  74.8

821.9  204.0
4384.1  636.8
165.1  20.5
16.6  12.1
20.7  4.9
142.5  18.4
104.1  13.0
19.5  6.0
312.6  144.3
88.1  34.3
392.8  111.7
264.2  53.6

0.42
0.66
0.52
0.33
0.53
0.63
0.61
0.50
0.56
0.52
0.65
0.66

0.0000
0.0001
0.0001
0.0003
0.0005
0.0005
0.0010
0.0009
0.0012
0.0016
0.0015
0.0021

0.0000
0.0049
0.0049
0.0206
0.0223
0.0225
0.0330
0.0330
0.0353
0.0369
0.0369
0.0465

Up-regulated
hsa-miR-31-3p
hsa-miR-143-5p
hsa-miR-30c-2-3p
hsa-miR-135b-5p

110.6  13.8
1.1  1.1
709.6  51.0
4.5  2.6

246.9  92.1
7.9  3.0
981.4  64.2
13.5  4.2

2.23
5.81
1.38
3.03

0.0000
0.0000
0.0011
0.0005

0.0018
0.0025
0.0348
0.0223

miRNA reads per million (rpm)
Cells treated with healthy human serum, n=4
3Cells treated with HNSCC patient serum, n=7
4Fold change in cancer serum compared with normal human serum
5False Discovery Rate
6Several differentially expressed miRNA were not found in Tarbase, so they were excluded from pathway
analysis
1
2
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Table 4. Gene Ontology terms for biological processes of target genes of 16 miRNAs differentially
expressed in cells treated with serum from healthy individuals compared with HNSCC patients

GO CATEGORY-BIOLOGICAL PROCESS

P-VALUE

Response to stress
Catabolic process
Viral process
Symbiosis, encompassing mutualism through parasitism
Biological_process
Biosynthetic process
Cellular nitrogen compound metabolic process
Cellular protein modification process
Gene expression
Mitotic cell cycle
Neurotrophin trk receptor signaling pathway
Cellular protein metabolic process
Cellular component assembly
MRNA metabolic process
Small molecule metabolic process
RNA metabolic process
Membrane organization
Fc-epsilon receptor signaling pathway
Nucleobase-containing compound catabolic process
Macromolecular complex assembly
DNA metabolic process
Epidermal growth factor receptor signaling pathway
Transcription, dna-templated
Cell death
Fibroblast growth factor receptor signaling pathway
Activation of signaling protein activity involved in unfolded
protein response
Blood coagulation
Viral life cycle
Immune system process
Protein complex assembly
Endoplasmic reticulum unfolded protein response
Cellular lipid metabolic process
Termination of rna polymerase ii transcription
TRIF-dependent toll-like receptor signaling pathway

Number of genes in each process targeted by miRNAs
Number of miRNAs targeting genes in each process

1
2

80

#GENES 1

#MIRNAS 2

0
0
0
0
0
0
0
0
0
3.33E-16
2.67E-13
3.89E-12
1.44E-11
6.96E-11
2.99E-10
8.23E-10
4.12E-09
2.08E-08
3.67E-08
2.67E-07
3.81E-06
5.96E-06
1.18E-05
2.68E-05
5.45E-05
3.01E-04

330
305
124
138
2006
665
813
425
171
93
54
80
184
48
307
53
98
35
128
122
87
38
286
128
35
17

6
7
7
7
8
8
8
9
9
8
5
5
5
5
6
5
5
5
5
5
2
3
3
4
3
4

8.64E-04
5.31E-03
7.60E-03
8.01E-03
8.49E-03
1.69E-02
2.33E-02
2.91E-02

58
14
136
82
18
24
10
18

3
2
3
3
2
2
2
3

Table 5. KEGG pathways of target genes of 16 miRNAs differentially expressed in cells treated with
serum from healthy individuals compared with HNSCC patients

KEGG PATHWAY

P-VALUE

#GENES 1

#MIRNAS 2

Pathways in cancer
PI3K-AKT signaling pathway
HTLV-I infection
Focal adhesion

1.23E-02
3.38E-02
3.24E-02
2.35E-03

95
82
68
62

11
12
12
11

Proteoglycans in cancer
Epstein-Barr virus infection
Viral carcinogenesis
Endocytosis
FOXO signaling pathway

1.51E-06
9.00E-03
1.80E-03
2.51E-02
2.35E-03

60
58
56
52
46

12
12
11
11
11

Hepatitis B
Protein processing in endoplasmic reticulum
RNA transport
Ubiquitin mediated proteolysis
Cell cycle

3.62E-03
2.51E-02
4.32E-02
2.48E-02
2.35E-03

46
45
44
41
40

12
10
11
10
10

Transcriptional misregulation in cancer
Signaling pathways regulating pluripotency of stem cells
Thyroid hormone signaling pathway
Neurotrophin signaling pathway
AMPK signaling pathway

4.32E-02
3.43E-02
8.07E-03
1.38E-02
4.32E-02

40
39
37
36
36

10
11
11
11
11

Oocyte meiosis
Small cell lung cancer
Choline metabolism in cancer
Prostate cancer
Adherens junction

1.69E-04
4.01E-04
5.34E-03
2.35E-03
7.74E-07

35
33
33
32
30

10
10
10
11
10

Estrogen signaling pathway
Bacterial invasion of epithelial cells
Erbb signaling pathway
Chronic myeloid leukemia
Progesterone-mediated oocyte maturation

3.62E-03
9.64E-05
1.62E-02
4.96E-04
3.28E-02

30
29
29
28
28

11
10
9
10
12

Salmonella infection
Glioma
Colorectal cancer
Apoptosis
P53 signaling pathway

4.05E-02
3.37E-06
6.49E-05
7.44E-03
9.00E-03

27
26
26
24
24

11
9
11
9
10

Prolactin signaling pathway
Non-small cell lung cancer

9.00E-03
1.69E-04

24
23

10
10
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KEGG PATHWAY

P-VALUE

#GENES 1

#MIRNAS 2

Shigellosis

2.35E-03

23

10

Pancreatic cancer
Renal cell carcinoma
Epithelial cell signaling in helicobacter pylori infection
Melanoma
Endometrial cancer

3.42E-03
3.50E-02
4.62E-02
2.96E-02
2.35E-03

23
22
22
21
20

9
8
7
8
11

Central carbon metabolism in cancer
Synaptic vesicle cycle
Bladder cancer
Lysine degradation
Thyroid cancer

3.24E-02
3.38E-02
1.61E-02
3.38E-02
5.23E-03

20
18
15
12
11

8
7
7
6
7

Fatty acid metabolism

5.16E-03

9

9

Number of genes in each pathway targeted by miRNAs
Number of miRNAs targeting genes in each pathway

1
2
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Figure 32. Gene expression changes in cells exposed to HNSCC patient serum.
Quantitative PCR was used to determine relative gene expression of several cancer-related genes. Primers
used for each analysis are listen in Table 6. SLC2a1 (p=0.0198), p53 (p=0.0011), cdc20 (p=0.0043), HRAS
(p=0.0306), Smarca4 (p=0.0235).
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Figure 33. KEGG pathway (152) analysis: Pathways in cancer.
Diagram of pathways in cancer genes and interactions. Genes highlighted in yellow are targeted by one of the
differently expressed miRNA and genes highlighted in orange are targeted by more than one miRNA.
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Table 6. List of primers used to determine relative gene expression.

GENE

PRIMER

SEQUENCE

B2M
B2M
TP53
TP53
RB1
RB1
CDC20
CDC20
SLC2A1
SLC2A1
DNMT1
DNMT1
DNMT3A
DNMT3A
DNMT3B
DNMT3B
CDKN2A
CDKN2A
SMARCA4
SMARCA4
CCND1
CCND1
GFP
GFP
HRAS
HRAS
NOTCH1
NOTHC1
MDM2
MDM2
PTEN
PTEN

F'
R'
F'
R'
F'
R'
F'
R'
F'
R'
F'
R’
F'
R'
F’
R’
F'
R'
F'
R'
F'
R'
F’
R'
F'
R'
F’
R’
F’
R’
F’
R’

5’-GAGTATGCCTGCCGTGTGAA-3’
5’-CGGCATCTTCAAACCTCCAT-3’
5’-GTGCAGCTGTGGGTTGATTC-3’
5’-GCCAGACCATCGCTATCTGA-3’
5’-TCAGAAGGTCTGCCAACACC-3’
5’-CAGAAGTCCCGAATGATTCACC-3’
5’-AATGCGCCAGAGGGTTATCA-3’
5’-CGGCCAGTACATTCCCAGAA-3’
5’-GAACTCTTCAGCCAGGGTCC-3’
5’-ACCACACAGTTGCTCCACAT-3’
5’-GATCGAGACCACGGTTCCTC-3’
5’-CGGCCTCGTCATAACTCTCC-3’
5’-GGGGGAGGCACTTGACAC-3’
5’-CTCTGTCAGCCTGTGGGTG-3’
5’-ATAAGTCGAAGGTGCGTCGT-3’
5’-TGTGCGTCTTCGAGTCTTGT-3’
5’-TGCCCAACGCACCGAAT-3’
5’-CGGGTGAGAGTGGCGG-3’
5’-CGCAAGGAGGTGGACTACAG-3’
5’-AGCGTGCCCTCCTCGAT-3’
5’-GCCGAGAAGCTGTGCATC-3’
5’-GGCCAGGTTCCACTTGAG-3’
5’-GCTCGATGCGGTTCACCAG-3’
5’- GCTCGATGCGGTTCACCAG-3’
5’-GGACGAATACGACCCCACTAT-3’
5’-TGTCCAACAGGCACGTCTC-3’
5’-AGCCTCAACGGGTACAAGTG-3’
5’-GCCACTGGTCATGTCTTTGC-3’
5’-AGGAGATTTGTTTGGCGTGC-3’
5’-TGAGTCCGATGATTCCTGCTG-3’
5’-ACTTGCAATCCTCAGTTTGTGG-3’
5’-AACTTGTCTTCCCGTCGTGT-3’
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CHAPTER FIVE: CONCLUSIONS

Summary
The studies outlined here provide evidence for tumorigenic processes involving epigenetic
regulation. We have demonstrated DNA methylation revision following DNA repair and epigenetic
activation of gene expression and aberrant miRNA and gene expression following exposure cancer
serum. The identity of the hypomethylating protein in HNSCC patient serum remains to be
determined.

Conclusions
Interconnections between gene regulation processes
The processes of DNA methylation, chromatin remodeling, and miRNA expression are
interdependent processes that concurrently regulate gene expression and are involved in
tumorigenesis. DNA methylation causes chromatin condensation through interaction with histone
modifiers (14-16), and chromatin structure can affect DNA methylation by blocking the accessibility
of demethylating enzymes (121,126-128). In addition to regulating gene expression, these processes
have been shown to regulate the expression of miRNAs (135-137) and, conversely, proteins
involved in this process can be regulated by miRNAs. These epigenetic and miRNA regulation
mechanisms form a network of processes with interconnected regulatory loops. Dysregulation of
any of these processes may also affect the others and together can contribute to tumorigenesis. The
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methylation revision following repair by NHEJ and the cancer-associated circulating protein that
were described in this study demonstrate the connection between these regulatory processes and the
development of cancer.

Identifying new targets for cancer epi-therapeutics
One important property of epigenetic alterations that makes them an ideal therapeutic target
is that they are reversible. This is in contrast to genetic mutations that are embedded in the DNA
sequence. In fact, hypomethylating drugs including 5’Aza-2’-deoxycitidine (Decitabine), and 1-β-Dribofuranosyl-2(1H)-pyrimidinone (Zebularine), have been shown to have positive effects when
used to treated cancer cells. The FDA has approved the use of Decitabine for treating
myelodysplastic syndrome and Zebularine for treating hematological malignancies (24,27,33,67).
Studies have also shown that antisense and small interfering RNA (siRNA) targeting DNA
methyltransferase mRNA can inhibit growth of colon and renal cell carcinoma cells (27,33). Further,
HDAC inhibitors, have been shown to selectively target and promote death in tumor cells. This lead
to approval of Voronistat, an HDAC inhibitor approved to treat cutaneous T-cell lymphoma. In
addition to increasing our knowledge of carcinogenic processes, uncovering the details of the
interaction between epigenetic and gene regulation processes observed in these studies can
potentially reveal new diagnostic and therapeutic targets in the inception, progression, and metastasis
of cancer.
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